Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination
- 31 March 2005
- journal article
- review article
- Published by Elsevier BV in Journal of Clinical Virology
- Vol. 32, 72-81
- https://doi.org/10.1016/j.jcv.2004.12.005
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- The epidemiology of human papillomavirus infectionsJournal of Clinical Virology, 2005
- Animal models of papillomavirus pathogenesisVirus Research, 2002
- Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasiaJournal of the American Academy of Dermatology, 2002
- Clinical studies of human papilloma vaccines in pre-invasive and invasive cancerVaccine, 2001
- Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasiaInternational Journal of Cancer, 2000
- Multiple mechanisms underlie HLA dysregulation in cervical cancerTissue Antigens, 2000
- Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%Antiviral Research, 1999
- The Human Papillomavirus E7 Oncoprotein Abrogates Signaling Mediated by Interferon-αVirology, 1999
- Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progressionThe Lancet, 1998
- A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancerThe Lancet, 1996